Trial Profile
Investigation of clinical efficacy of aflicbercept in patients with polypoidal choroidal vasculopathy (PCV) with resistance of ranibizumab
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- Sponsors Bayer Yakuhin
- 02 Dec 2016 Status changed from recruiting to discontinued.
- 21 Jan 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan
- 09 Dec 2013 New trial record